Host immunity recognizes and eliminates most early tumor cells, yet immunological
checkpoints, exemplified by CTLA-4, PD-1, and PD-L1, pose a significant obstacle to …

The advent of large-scale microbiome studies affords newfound analytical opportunities to
understand how these communities of microbes operate and relate to their environment …

The GeneCards® database of human genes was launched in 1997 and has expanded
since then to encompass gene-centric, disease-centric, and pathway-centric entities and …

The discovery of drivers of cancer has traditionally focused on protein-coding genes,,–. Here
we present analyses of driver point mutations and structural variants in non-coding regions …

Transcript alterations often result from somatic changes in cancer genomes. Various forms of
RNA alterations have been described in cancer, including overexpression, altered splicing …

Summary Enhancer of Zeste 2 (EZH2) is the enzymatic subunit of Polycomb Repressive
Complex 2 (PRC2), which catalyzes histone H3 lysine 27 trimethylation (H3K27me3) at …

The functional engagement between an enhancer and its target promoter ensures precise
gene transcription. Understanding the basis of promoter choice by enhancers has important …

Age-related accumulation of postzygotic DNA mutations results in tissue genetic
heterogeneity known as somatic mosaicism. Although implicated in aging as early as the …

Cell lines are key tools for preclinical cancer research, but it remains unclear how well they
represent patient tumor samples. Direct comparisons of tumor and cell line transcriptional …

Although better science and technology has been linked with better health care, however,
reality is much different. Although America and most of Europe are equipped with most …